A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42

BACKGROUND: The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based thera...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Mamounas, Eleftherios P., Bandos, Hanna, Lembersky, Barry C., Jeong, Jong-Hyeon, Geyer, Charles E., Rastogi, Priya, Fehrenbacher, Louis, Graham, Mark L., Chia, Stephen K., Brufsky, Adam M., Walshe, Janice M., Soori, Gamini S., Dakhil, Shaker R., Seay, Thomas E., Wade, James L., McCarron, Edward C., Paik, Soonmyung, Swain, Sandra M., Lawrence Wickerham, D., Wolmark, Norman
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6691732/
https://ncbi.nlm.nih.gov/pubmed/30509771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30621-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars